otsuka-us.com
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment | Otsuka US
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION trial eval...